Vanguard Group’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $423M | Buy |
29,702,696
+168,667
| +0.6% | +$1.66M | 0.01% | 1154 |
|
|
2025
Q3 | $233M | Buy |
29,534,029
+126,441
| +0.4% | +$900K | ﹤0.01% | 1469 |
|
|
2025
Q2 | $169M | Buy |
29,407,588
+356,967
| +1% | +$2.3M | ﹤0.01% | 1590 |
|
|
2025
Q1 | $237M | Sell |
29,050,621
-208,342
| -0.7% | -$1.93M | ﹤0.01% | 1400 |
|
|
2024
Q4 | $276M | Buy |
29,258,963
+458,143
| +2% | +$4.76M | ﹤0.01% | 1382 |
|
|
2024
Q3 | $308M | Buy |
28,800,820
+212,214
| +0.7% | +$2.31M | 0.01% | 1315 |
|
|
2024
Q2 | $284M | Buy |
28,588,606
+384,297
| +1% | +$3.94M | 0.01% | 1299 |
|
|
2024
Q1 | $332M | Sell |
28,204,309
-288,177
| -1% | -$3.69M | 0.01% | 1228 |
|
|
2023
Q4 | $404M | Buy |
28,492,486
+1,360,613
| +5% | +$15.4M | 0.01% | 1096 |
|
|
2023
Q3 | $330M | Buy |
27,131,873
+107,456
| +0.4% | +$1.39M | 0.01% | 1150 |
|
|
2023
Q2 | $339M | Buy |
27,024,417
+162,472
| +0.6% | +$1.93M | 0.01% | 1157 |
|
|
2023
Q1 | $298M | Buy |
26,861,945
+323,574
| +1% | +$3.99M | 0.01% | 1217 |
|
|
2022
Q4 | $324M | Buy |
26,538,371
+667,309
| +3% | +$7.51M | 0.01% | 1125 |
|
|
2022
Q3 | $270M | Buy |
25,871,062
+138,973
| +0.5% | +$1.55M | 0.01% | 1198 |
|
|
2022
Q2 | $276M | Buy |
25,732,089
+74,919
| +0.3% | +$617K | 0.01% | 1229 |
|
|
2022
Q1 | $243M | Buy |
25,657,170
+11,986
| +0% | +$112K | 0.01% | 1428 |
|
|
2021
Q4 | $296M | Buy |
25,645,184
+1,156,583
| +5% | +$12.9M | 0.01% | 1357 |
|
|
2021
Q3 | $234M | Sell |
24,488,601
-240,799
| -1% | -$2.46M | 0.01% | 1509 |
|
|
2021
Q2 | $238M | Buy |
24,729,400
+342,347
| +1% | +$3.34M | 0.01% | 1527 |
|
|
2021
Q1 | $241M | Buy |
24,387,053
+541,620
| +2% | +$8.38M | 0.01% | 1479 |
|
|
2020
Q4 | $551M | Buy |
23,845,433
+657,866
| +3% | +$13.5M | 0.02% | 836 |
|
|
2020
Q3 | $327M | Sell |
23,187,567
-925,169
| -4% | -$13.5M | 0.01% | 976 |
|
|
2020
Q2 | $364M | Sell |
24,112,736
-5,850
| -0% | -$71.3K | 0.01% | 909 |
|
|
2020
Q1 | $223M | Buy |
24,118,586
+359,426
| +2% | +$3.42M | 0.01% | 1072 |
|
|
2019
Q4 | $231M | Buy |
23,759,160
+475,551
| +2% | +$4.35M | 0.01% | 1308 |
|
|
2019
Q3 | $187M | Buy |
23,283,609
+952,948
| +4% | +$10.3M | 0.01% | 1372 |
|
|
2019
Q2 | $279M | Buy |
22,330,661
+2,510,118
| +13% | +$31.9M | 0.01% | 1154 |
|
|
2019
Q1 | $270M | Buy |
19,820,543
+2,648,546
| +15% | +$32.4M | 0.01% | 1154 |
|
|
2018
Q4 | $165M | Buy |
17,171,997
+364,225
| +2% | +$4M | 0.01% | 1367 |
|
|
2018
Q3 | $203M | Buy |
16,807,772
+541,308
| +3% | +$7.57M | 0.01% | 1375 |
|
|
2018
Q2 | $254M | Buy |
16,266,464
+612,170
| +4% | +$9.25M | 0.01% | 1192 |
|
|
2018
Q1 | $235M | Buy |
15,654,294
+2,019,509
| +15% | +$30.7M | 0.01% | 1181 |
|
|
2017
Q4 | $196M | Buy |
13,634,785
+353,917
| +3% | +$4.86M | 0.01% | 1317 |
|
|
2017
Q3 | $200M | Buy |
13,280,868
+4,162,622
| +46% | +$55.1M | 0.01% | 1268 |
|
|
2017
Q2 | $91.8M | Buy |
9,118,246
+430,486
| +5% | +$3.46M | ﹤0.01% | 1723 |
|
|
2017
Q1 | $61.9M | Buy |
8,687,760
+353,949
| +4% | +$2.24M | ﹤0.01% | 1898 |
|
|
2016
Q4 | $41.4M | Buy |
8,333,811
+377,268
| +5% | +$2.61M | ﹤0.01% | 2072 |
|
|
2016
Q3 | $58.9M | Buy |
7,956,543
+923,043
| +13% | +$6.23M | ﹤0.01% | 1856 |
|
|
2016
Q2 | $38.4M | Buy |
7,033,500
+524,050
| +8% | +$3.66M | ﹤0.01% | 2019 |
|
|
2016
Q1 | $55M | Buy |
6,509,450
+281,883
| +5% | +$2M | ﹤0.01% | 1822 |
|
|
2015
Q4 | $60.4M | Buy |
6,227,567
+414,956
| +7% | +$3.74M | ﹤0.01% | 1797 |
|
|
2015
Q3 | $81.3M | Buy |
5,812,611
+2,524,535
| +77% | +$39.6M | 0.01% | 1583 |
|
|
2015
Q2 | $46.5M | Buy |
3,288,076
+737,348
| +29% | +$8.86M | ﹤0.01% | 1980 |
|
|
2015
Q1 | $27.8M | Buy |
2,550,728
+173,039
| +7% | +$1.53M | ﹤0.01% | 2190 |
|
|
2014
Q4 | $19.8M | Buy |
2,377,689
+604,358
| +34% | +$4.15M | ﹤0.01% | 2242 |
|
|
2014
Q3 | $10.6M | Buy |
1,773,331
+412,161
| +30% | +$2.16M | ﹤0.01% | 2464 |
|
|
2014
Q2 | $4.55M | Buy |
1,361,170
+129,429
| +11% | +$304K | ﹤0.01% | 2882 |
|
|
2014
Q1 | $2.55M | Buy |
1,231,741
+41,260
| +3% | +$103K | ﹤0.01% | 3115 |
|
|
2013
Q4 | $2.8M | Buy |
1,190,481
+99,019
| +9% | +$217K | ﹤0.01% | 3055 |
|
|
2013
Q3 | $2.53M | Sell |
1,091,462
-1,235
| -0.1% | -$3.1K | ﹤0.01% | 3047 |
|
|
2013
Q2 | $2.55M | Buy |
+1,092,697
| New | +$3.36M | ﹤0.01% | 2982 |
|
Other funds holding FOLD
HI
PCM
BG
PA
Vanguard Group's FOLD Position: Q4 2025 in Review
Vanguard Group increased its Amicus Therapeutics (FOLD) stake by 0.57% in Q4 2025, buying an estimated $1.66M and bringing the position to 29,702,696 shares worth $423M. The position accounts for 0.01% of the portfolio, ranked #1154.
Vanguard Group first reported a position in FOLD in Q2 2013 and has held it in 51 quarters since. The position peaked at $551M in Q4 2020. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.
- Vanguard Group held 29,702,696 shares of Amicus Therapeutics worth $423M as of Q4 2025.
- Vanguard Group bought 168,667 Amicus Therapeutics shares in Q4 2025, an estimated $1.66M.
- Amicus Therapeutics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1154 holding.
- Vanguard Group first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Amicus Therapeutics position peaked at $551M in Q4 2020.
- 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.